id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12675 R47890 |
Mari (Carbamazepine), 2022 | Abortion | throughout pregnancy | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 0.37 [0.01;19.78] C | 0/29 0/11 | 0 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12901 R48933 |
Hosny (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 | Induced abortion | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.02 [0.00;2.02] C excluded (control group) |
0/31 0/1 | 0 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12902 R48936 |
Hosny (Carbamazepine) (Controls unexposed, sick), 2021 | Induced abortion | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.67 [0.01;35.25] C | 0/31 0/21 | 0 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7415 R21828 |
Miškov (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2016 | Artificial abortion | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.95 [0.04;24.78] C excluded (control group) |
0/13 1/37 | 1 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7043 R19887 |
Miškov (Carbamazepine) (Controls unexposed, disease free), 2016 | Artificial abortion | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
10.20 [0.19;536.57] C excluded (control group) |
0/13 0/128 | 0 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7409 R21800 |
Miškov (Carbamazepine) (Controls unexposed, sick), 2016 | Artificial abortion | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.28 [0.00;16.82] C | 0/13 0/4 | 0 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6290 R16969 |
Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Induced abortions | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.93 [0.86;4.30] C | 15/1,718 10/2,198 | 25 | 1,718 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6611 R18138 |
Holmes (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 | Elective termination | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Controls: mixed indications |
0.41 [0.05;3.70] C excluded (control group) |
1/573 4/948 | 5 | 573 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5877 R14644 |
Holmes (Carbamazepine) (Controls unexposed, disease free), 2011 | Elective termination | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 0.99 [0.04;24.52] C | 1/573 0/190 | 1 | 573 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5578 R14507 |
Diav-Citrin (Carbamazepine), 2001 | Elective termination of pregnancy | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 2.30 [0.86;6.13] C | 9/108 8/210 | 17 | 108 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 1.82 [1.01;3.28] | 43 | 2,472 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick; 4: Carbamazepine) (Controls exposed to Lamotrigine, sick; 5: Carbamazepine) (Controls unexposed, disease free; 6: Carbamazepine;
Asymetry test p-value = 0.0089 (by Egger's regression)
slope=1.1259 (0.1388); intercept=-0.8958 (0.1883); t=4.7582; p=0.0089
excluded 6611, 7415, 7043, 12901